Investigated for treating COVID-19.
See also separate entry for sofosbuvir.
- TRADE NAME: Harvoni (Gilead)
- INDICATIONS: Hepatitis C
- CLASS: Covid-19 putative drug, Hepatitis C virus NS5A inhibitor (ledipasvir), Hepatitis C virus nucleotide analog NS5B polymerase inhibitor (sofosbuvir)
- HALF-LIFE: 47 hours (ledipasvir); <27 hours (sofosbuvir)
- FDA APPROVAL DATE: 10/10/2014
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Amiodarone, Carbamazepine, Cobicistat/Elvitegravir/Emtricitabine/Tenofovir Disoproxil, Doravirine/Lamiduvine/Tenofovir Disoproxil, Oxcarbazepine, Phenobarbital, Phenytoin, Rifabutin, Rifampin, Rifapentine, Ritonavir, Rosuvastatin, Simeprevir, St John's Wort, Tenofovir Disoproxil - PREGNANCY: Insufficient evidence to inform drug-associated risk; contra-indicated in pregnancy when given with ribavirin
- See adverse reactions attributed to class:
Please login to view the rest of this drug profile.
Click on the DRUG REVIEW ARTICLE tab (above) to see a review of ledipasvir & sofosbuvir in the Taylor & Francis journal Expert Opinion on Drug Safety.
(Note that non-subscribers to the journal will only be able to see an abstract of the article.)
Page last updated 06/10/2025
